Optiv Security Announces New Risk Transformation Service™ to Help Organizations Mitigate Enterprise Risk
Most organizations conduct annual risk assessments, identify gaps, and receive recommendations for how to remediate those gaps. But many lack the resources to follow through on planning and operationalization. Based on strategies developed or assessments performed, many organizations know what to do but often not how to do it. Optiv Security, the world’s leading security solutions integrator, today announced its new Risk Transformation ServiceTM, an end-to-end solution that includes strategy execution.
Designed to enable clients around the world to better evaluate current risk against acceptable risk, Optiv’s Risk Transformation ServiceTM helps clients develop strategies that drive cohesive cybersecurity programs, execute on those strategies to mitigate enterprise risk, and achieve measurable outcomes. The service puts business strategy and risk at the heart of cyber decision-making with two distinct options:
- The Enterprise Risk Transformation Service TM helps organizations execute on risk transformation based on business objectives, results of an existing strategy or assessment, and a list of desired improvements or future mode of operation. This service includes program management, quality assurance and oversight over all or parts of a transformation or remediation initiative.
- The Quickstart Risk Transformation Service TM enables mid-sized organizations to get started with a risk-centric model for cybersecurity and aids them in the first steps of execution of their transformation roadmap. Optiv helps these clients set and execute a strategy, engaging with them from start to finish.
“Organizations today are adopting new risk and compliance principles to achieve business resilience,” said Dustin Owens, Optiv’s vice president, risk advisory. “As IT risk management evolves to more holistic operational risk management, it is being integrated into the fabric of organizations. This means that security teams are now a critical component to the overall business risk strategy.”
Owens continued, “As a result, adaptive, risk-based decision-making is becoming core to business agility and resilience, taking over from the antiquated check-the-box, compliance-based approach of the past. It’s high time for companies to embrace the risk revolution. They need to take a stance against the outside-in approach – which is predicated on continuously responding to legislative and regulatory requirements, specific threats, and other outside factors – and rewrite how they manage cybersecurity by proactively addressing all aspects of cybersecurity risk, including privacy and governance, cyber resilience, and risk optimization.”
Optiv’s new Risk Transformation ServiceTM is part of the company’s complete continuum of fully integrated cybersecurity risk services, which are focused on resolving three prevalent business issues:
- The need for risk governance – Optiv helps clients understand where critical assets are located, why they are important, how they are protected and who has access; and as these variables change, how their risk profile changes. This enables organizations to make security decisions based on risk so they can move faster, safely.
- Volume and velocity of change – Optiv allows clients to embrace the fast pace of digital transformation initiatives and deal with constant operational chaos simultaneously by helping them execute adaptive cyber resilience capabilities.
- Articulating security health to the business and board – Optiv provides security teams with everything they need to articulate risk and security performance in business terms by enabling them to effectively measure, monitor and report on security posture and align security to business objectives. This allows security teams to influence better decision-making and improve overall business health.
Please visit Optiv’s website to learn more about risk transformation or the company’s overarching approach to risk management.
Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn:
www.linkedin.com/company/optiv-inc
Facebook:
www.facebook.com/optivinc
YouTube:
www.youtube.com/c/OptivInc
Blog:
www.optiv.com/explore-optiv-insights/blog
About Optiv Security
Optiv helps clients plan, build and run successful cybersecurity programs that achieve business objectives through our depth and breadth of cybersecurity offerings, extensive capabilities and proven expertise in cybersecurity, integration and cyber operational services. Optiv maintains premium partnerships with more than 350 of the leading cybersecurity technology manufacturers. For more information, visit www.optiv.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190306005475/en/
Contact information
Brett Ater
(913) 304-7683
Brett.ater@optiv.com
or
Jason
Cook
(816) 701-3374
Jason.cook@optiv.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom